News articles about ADMA Biologics (NASDAQ:ADMA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ADMA Biologics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.9942247412358 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of ADMA Biologics (ADMA) opened at $3.66 on Friday. ADMA Biologics has a 52-week low of $2.01 and a 52-week high of $5.74. The company has a market cap of $94.40, a PE ratio of -1.83 and a beta of 2.09. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Friday, November 3rd. The biotechnology company reported $0.59 earnings per share for the quarter, topping the consensus estimate of ($0.51) by $1.10. ADMA Biologics had a negative net margin of 35.00% and a negative return on equity of 76.26%. research analysts anticipate that ADMA Biologics will post -2.28 EPS for the current year.
ADMA has been the subject of several research analyst reports. Raymond James Financial raised shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research note on Tuesday, November 14th. Maxim Group reissued a “buy” rating and set a $8.00 target price (down from $13.00) on shares of ADMA Biologics in a research report on Monday, December 11th.
In related news, insider Adam S. Grossman bought 485,000 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were purchased at an average cost of $2.15 per share, for a total transaction of $1,042,750.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Eric I. Richman bought 25,000 shares of the company’s stock in a transaction on Thursday, November 9th. The stock was bought at an average price of $2.15 per share, for a total transaction of $53,750.00. Following the completion of the purchase, the director now owns 31,300 shares of the company’s stock, valued at $67,295. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 526,500 shares of company stock worth $1,131,975. 60.44% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/19/adma-biologics-adma-getting-somewhat-positive-press-coverage-study-shows.html.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.